Metastatic Alveolar Soft Part Sarcoma (DBCOND0069675)

Identifiers

Synonyms

Alveolar soft part sarcoma metastatic

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Atezolizumab	A monoclonal antibody used to treat advanced or metastatic urothelial carcinoma with disease progression during or up to 12 months after platinum-containing chemotherapy.	Programmed cell death 1 ligand 1target Programmed cell death protein 1target

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06066138	A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing	Atezolizumab	treatment	1	not_yet_recruiting
NCT05333458	Testing Atezolizumab With or Without Selinexor in Patients >= 18 Years Old With Alveolar Soft Part Sarcoma, the Axiom Study	Atezolizumab Escitalopram Selinexor	treatment	2	recruiting
NCT03141684	Testing Atezolizumab Alone or Atezolizumab Plus Bevacizumab in People With Advanced Alveolar Soft Part Sarcoma	Atezolizumab Bevacizumab	treatment	2	active_not_recruiting
NCT02113826	Pazopanib for Metastatic Alveolar Soft Part Sarcoma	Pazopanib	treatment	2	terminated
NCT03233698	Atezolizumab in Treating Patients With Newly Diagnosed and Metastatic Alveolar Soft Part Sarcoma That Cannot Be Removed by Surgery	Atezolizumab	treatment	2	recruiting